Block Listing Six Monthly Return

Futura Medical PLC

30 November 2023

 

Block Listing Six Monthly Return

30 November 2023

Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).

Name of applicant:		Futura Medical Plc
Name of scheme(s):		Unapproved Share Option Scheme Unapproved Share Incentive Scheme EMI Share Option Scheme LTIP Scheme
Period of return:	From:	1 June 2023	To:	30 November 2023
Balance of unallotted securities under scheme(s) from previous return:		12,526,721
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		LTIP: 10,590,675
Less:  Number of securities issued/allotted under scheme(s) during period:		USOS: nil EMI: 756,000 LTIP: 1,578,731
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		20,782,665
Number and class of securities originally admitted and the date of admission		USOS Total: 3,882,912 814,424 25 May 2011 1,202,280             8 October 2013 1,466,208             25 May 2017 400,000 30 May 2018 USIS Total: 425,000 425,000 30 November 2018 EMI Total: 8,112,088 1,520,576             25 May 2011 1,467,720             8 October 2013 1,893,792             25 May 2017 790,000 30 May 2018 1,340,000             30 November 2018 1,100,000           2 February 2023 LTIP Total:  15,035,617     4,444,942            2 February 2023 10,590,675          3 November 2023

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: [e-mail]

Tel: [phone]

www.futuramedical.com

Nominated Adviser and Sole Broker:

Liberum

Phil Walker / Ben Cryer

Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Nick Bastin/ Jonathan Edwards/ Elena Bates

Email: [e-mail]

Tel: [phone]

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a novel treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted two Phase 3 studies using MED3000 in ED; FM57 study which enabled Futura to be granted a CE Mark in 2021 and FM71 which enabled Futura to be granted US marketing authorisation. Both studies demonstrated that MED3000 presents an effective clinically proven treatment for ED with a rapid speed of onset and a favourable benefit versus risk profile ideally suited for an 'Over the Counter' classification.

Eroxon® is FDA approved in the US, CE marked in Europe and UKCA marked in the UK as a clinically proven topical treatment for adult men with erectile dysfunction under the brand Eroxon® with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is the agreed brand name in certain regions such as the EU whereas MED3000 continues to be the internal code name used by the Company and also in reference to countries where regulatory approval or commercial distribution agreements have not yet been achieved. www.eroxon.com

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.

 

END